Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L. Kindler, Jose A. Lopez-Martin, Wilson H. Miller, Antoine Italiano, Steven Kao, Sarina A. Piha-Paul, Jean Pierre Delord, Robert R. McWilliams, David A. Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin NorwoodYung Jue Bang

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)

Fingerprint Dive into the research topics of 'Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study'. Together they form a unique fingerprint.

Medicine & Life Sciences